Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $47 to $48.

May 31, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical and raises the price target from $47 to $48.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The slight increase in the price target from $47 to $48 indicates a modestly positive outlook but not enough to change the overall rating.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100